From Coverage to Cure: a data-driven roadmap to accelerate Universal Health Insurance and secure patients' access to medicines in Egypt
Egypt's Universal Health Insurance (UHI) system, established by Law No. 2 of 2018, is the state's flagship instrument for delivering Egypt Vision 2030's commitment to accessible, quality healthcare for every citizen. Phase one is complete in six governorates, and phase two — led by Minya and covering more than 12 million people — is now under way. In October 2026 a Prime Ministerial committee set the direction clearly: plan for completion within no more than ten years and cover 50% of the population by 2030. Accelerating coverage at this pace is not only a question of hospitals and enrolment; it is a question of medicines. Every new beneficiary becomes a prescription that must be forecast, procured, priced, manufactured and dispensed. Egypt has strong foundations: a WHO Maturity Level 3 regulator, local production that meets about 91% of medicine needs, a single public bulk purchaser, and more than 81 million electronic prescriptions inside UHI itself. This policy brief argues that the speed of UHI will increasingly be set by the medicines value chain. It proposes five practical, low-cost measures: a national UHI Medicines Intelligence Platform that links existing data into one forecasting layer; a standard Medicine Readiness Study before each governorate enters the system; multi-year, volume-based "local-first" framework agreements to support manufacturing and API localisation; an institutionalised health technology assessment and managed-entry pathway for high-cost medicines; and a last-mile pharmacy access network, starting in Minya. The recommendations require coordination more than new spending, and each can be piloted within the current legal framework. An Arabic version of the full paper is included as an additional file.
Authors
- Mohammad Osama Alsaadany
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-15
- DOI
- https://doi.org/10.5281/zenodo.24245770
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00